The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs
Pei Y. Liu(Capital Medical University), Tao Liu(Cancer Clinic), Rui Yang(Tianjin University of Science and Technology), Faraz Siddiqi(UNSW Sydney), Maria Kavallaris(Cancer Institute of New South Wales), Bernard Atmadibrata(UNSW Sydney), Thomas J. Telfer(The University of Sydney), Rachel Codd(The University of Sydney), Jenny Wang(Columbia University Irving Medical Center), David S. Ziegler(Cancer Institute of New South Wales), Marcel E. Dinger(The University of Sydney), Ken Itoh(Hirosaki University), Michelle Haber(Cancer Clinic), Xu Dong Zhang(Zhengzhou University), Nicholas Sokolowski(UNSW Sydney), Glenn M. Marshall(The University of Sydney), Jennifer A. Byrne(The University of Sydney), Su Guo(QB3), Bing Liu(UNSW Sydney), Yuting Sun(Baotou Medical College), Xiang Guo(Shanxi Medical University), Joshua A. McCarroll(Cancer Institute of New South Wales), Andrew E. Tee(UNSW Sydney), Denise Yu(UNSW Sydney), Murray D. Norris(Cancer Clinic), Lihong Zhang(Northeast Normal University), Belamy B. Cheung(Children's Cancer Institute Australia)
Cited by 21
Related Papers
Comprehensive Analysis of Hypermutation in Human Cancer
|Cell|2017|795
Regulation of PD-L1: a novel role of pro-survival signalling in cancer
|Annals of Oncology|2015|761
Long noncoding RNAs in mouse embryonic stem cell pluripotency and differentiation
|Genome Research|2008|742
Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.
|Journal of Clinical Investigation|1997|598
Genome-wide analysis of long noncoding RNA stability
|Genome Research|2012|592